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ScienceDirectPeptide loading of class II MHC molecules in endosomal
compartments is regulated by HLA-DM. HLA-DO modulates
HLA-DM function, with consequences  for the spectrum of
MHC-bound epitopes presented at the cell surface for
interaction with T cells. Here, we summarize and discuss
recent progress in investigating the molecular mechanisms
of action of HLA-DM and HLA-DO and in understanding their
roles in immune responses. Key findings are the long-
awaited structures of HLA-DM in complex with its class II
substrate and with HLA-DO, and observation of a novel
phenotype — autoimmunity combined with
immunodeficiency — in mice lacking HLA-DO. We also
highlight several areas where gaps persist in our knowledge
about this pair of proteins and their molecular biology and
immunobiology.
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Introduction
HLA-DM and HLA-DO and their murine counterparts
H-2M and H-2O (generically referred to here as DM and
DO) are non-peptide binding class II major histocompat-
ibility (MHC-II) homologs. Unlike the large family of
class I MHC homologs, which have varied roles in many
cell types as endocytic receptors, NK ligands, T cell
decoys, and presenters of peptides, lipids, and vitamin
derivatives [1], for the non-classical MHC-II proteins DM
and DO known roles are only in antigen-presenting cells,
Open access under CC BY license.www.sciencedirect.com where they regulate loading of peptides derived from
self and foreign antigens. DM functions as a peptide
exchange factor required for efficient loading of endoso-
mal peptides onto MHC-II molecules. DO functions as a
modulator of DM. The molecular mechanism by which
DM promotes peptide exchange and the roles of DM and
DO in the overall immune response are outstanding
fundamental questions in MHC biology. In the period
covered by this review, significant progress has been
made towards understanding the structural basis for
DM interaction with MHC-II, and new work strength-
ens the conclusion that DM plays a key role in
immunodominance. However, important mechanistic
questions about DM action still remain unanswered,
and this constrains our ability to integrate these
advances into deeper understanding of how DM func-
tions in development, maintenance, and activation of
the CD4+ T cell response. For DO, the mechanism of
action has been established: DO acts as substrate mimic
to competitively inhibit HLA-DM-mediated  catalysis of
MHC-II peptide exchange. A key role for DO in reg-
ulating autoimmunity has been revealed through studies
of H-2O knockout mice. However, the relationship of
the molecular mechanism of DO action to its biological
role still is not clear.
Insight into DM function from crystal
structures of DM-DO and DM-DR
Two crystal structures of trapped DM-MHC complexes
provided long-awaited insight into how DM engages
MHC-II to promote peptide exchange [2,3]. DM acts
as an enzyme to catalyze peptide exchange [4,5], and like
other enzymes it binds only transiently to its substrate(s)
before inducing conversion and releasing product(s). Thus,
DM does not bind stably to MHC-peptide complexes
[6,7]. DM does not appear to bind to recombinant pep-
tide-free empty MHC molecules [7], although DM bind-
ing to apparently empty MHC molecules produced in their
normal cellular context has been reported [8,9]. The dis-
crepancy may be due to differences between metastable
‘peptide-receptive’ species generated during peptide dis-
sociation [9–11] and stable ‘peptide-averse’ species pro-
duced in the absence of peptide [11,12]. Previously, a few
mutated HLA-DR-peptide complexes with weakened
MHC-peptide interaction have been shown to bind to
DM sufficiently tightly to be observed biochemically
[6,7,13], but until recently all of these have resisted
crystallization and detailed structural analysis. In one of
the recent structure reports, Pos et al. crystallized a DM-
MHCII complex after covalent attachment of DM toCurrent Opinion in Immunology 2014, 26:115–122
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beta-subunit C-terminus to the HLA-DR1 beta-subunit C-
terminus, with the HLA-DR1 carrying a truncated peptide
attached via a disulfide bond engineered into the P6 pocket
[2]. The peptide was designed to bind only to the C-
terminal side of the binding site, leaving the N-terminal
side empty; usually such peptides bind weakly if at all, but
here the interaction was stabilized through covalent bond-
ing to the MHC. Crucially, leaving the N-terminal side of
the site open allows MHC conformational alteration and
stable interaction with DM. In the second of the crystal
structure reports, Guce et al. crystallized DM with HLA-
DO [3]. In the complex, DO adopts an overall confor-
maton highly similar to classical MHCII proteins with an
open groove, but with conformational alterations at the N-
terminal side. The DO structure provides insight into the
nature of ab chain association in the MHCII family and
constrains possible functional roles for DO in antigen
presentation. DO was shown through enzymatic and muta-
genesis studies to act as a substrate mimic, binding tightly
to DM and competitively inhibiting the interaction with
MHC-peptide. In the crystal structure DO was observed to
bind to the same lateral face of DM as does DR, with
essentially all interface residues conserved.Figure 1
(a)
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DM engages DR1 and DO similarly. (a) Structure of DM bound to HLA-DR1
intermediate, from PDB:4FZQ described in Pos et al. [2]. (b) DM bound to 
from PDB:4IOP described in Guce et al. [3].
Current Opinion in Immunology 2014, 26:115–122 The DM-MHC interaction in the two structures is nearly
identical (Figure 1), alleviating concerns that the protein
engineering necessary to trap DM with HLA-DR might
have induced a non-physiologically relevant confor-
mation, or that DO’s mimicry of an MHC-peptide com-
plex might not extend to structural details of its interaction
with DM. A FRET study revealed a similar side-by-side
arrangement for DM bound to DO in solution [14], further
supporting the physiological relevance of the complex
visually by X-ray crystallography.
The crystal structures reveal an extensive interface be-
tween DM and MHC-II involving both membrane-prox-
imal immunoglobulin-like domains and membrane-distal
helices-atop-sheet domains, generally corresponding to the
lateral surfaces previously identified by mutagenesis
[15,16]. The interaction is surprisingly asymmetric, given
the structural homology between DM and both HLA-DR
and HLA-DO, and involves surfaces not previously
observed to be involved in interactions of MHC proteins
with other binding partners. Compared to crystal structures
of DM alone [17–19], DM does not undergo any appreci-
able conformational alteration upon DR/DO binding, but
HLA-DR undergoes a dramatic change in residues 35–57Rβ
β
Current Opinion in Immunology
 carrying a covalently attached peptide fragment to mimic a reaction
DO, a tight-binding competitive inhibitor that acts as a substrate mimic,
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Figure 2
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Conformational alteration in DM–DR1-peptide and DM–DO occludes the P1 regions of the MHCII peptide-binding site. (a) Major structural alterations
are restricted to residues 35–57 in the MHCII alpha subunit (boxed), involving strands 3 and 4 of the beta sheet platform (s3–s4 region), the MHCII 3–10
helix adjacent to the peptide binding site, and the extended strand region alongside the P1 pocket. (b) These alterations sterically occlude the N-
terminal side of the peptide-binding site. Locations of the peptide side-chain binding pockets are indicated after notional removal of the peptide from
the structure of DR1 bound to an influenza-derived peptide.of the alpha subunit (boxed in Figure 2a). This region
comprises the last two strands (s3–s4) of the beta-sheet
‘floor’ of the peptide-binding site, the short 3–10 helix at
the N-terminal end of the site, and the extended strand
region in the vicinity of the P1 pocket. The structure of
free HLA-DO has not been determined, so whether or
not it undergoes conformational change upon binding
DM is not known, but HLA-DO in complex with DM
assumes a conformation that is similar to the altered
MHC-II-peptide structure in the DM/DR complex
(Figure 2a). The conformation includes a flipped-out
orientation of Trpa43, previously identified as a crucial
for the DM/DR interaction [6], and occlusion of the N-
terminal side of the peptide-binding site (Figure 2b).
The extended strand rearrangement places a phenyl-
alanine in the P1 pocket (Phea51 for HLA-DR, Phea54
for HLA-DO) and disrupts hydrogen-bonding inter-
actions between the extended strand and the peptide
main-chain atoms. Both the P1 pocket and the main-
chain hydrogen bonds in this region are known to be
important for stabilizing MHC-peptide interaction.
Thus the structures provide a straightforward molecular
mechanism for DM-catalyzed peptide exchange, in
which DM binding destabilizes the MHC-peptidewww.sciencedirect.com complex by interfering with key peptide main chain
and side chain binding interactions.
Determinants for DM action
Much recent effort in the field has been devoted to
identifying features of the MHCII-peptide complex
associated with susceptibility to editing by DM. Resist-
ance to DM editing is thought to be a key aspect of CD4+
T cell epitope selection. Yin et al. validated this idea in
the context of the long-term memory response to small-
pox vaccination, adding to the existing literature of stu-
dies in mice [20]. Various features of the MHC-peptide
interaction were measured for HLA-DR1 and a series of
peptides from the vaccinia A10L major core protein, and
the dissociation lifetime in the presence of DM was found
to be the best predictor of immunogenicity. Chaves et al.
reviewed currently available algorithms for predicting
CD4+ T cell epitopes and concluded that, while these
algorithms are useful for many aspects of epitope dis-
covery, their prediction efficiency remains poor [21]. It is
likely that approaches that take into account the action of
DM would have greatly improved prediction efficiency.
However, the peptide sequence determinants for DM
editing are not yet clear.Current Opinion in Immunology 2014, 26:115–122
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a key feature determining DM susceptibility. For HLA-
DR (and its murine counterpart I-E), the P1 pocket is
the largest and most important energetically of the
MHCII peptide side-chain binding pockets. The P1
pocket becomes sterically blocked in the DM-MHCII
peptide complexes as a result of the DM-induced con-
formational change (Figure 2). Anders et al. found that
HLA-DR molecules carrying truncated peptides that
left the P1 pocket vacant bound tightly to DM [6]. As
the P1 pocket is the major determinant of peptide
binding affinity, the truncated peptides bound only very
weakly to DR, but could be trapped in the site by
engineered disulfide bonds. In a subsequent study,
Schulze et al. found that that truncated peptides that
retained P1 pocket occupancy were resistant to DM
[22]. These considerations led Pos et al. to a model
whereby the ability of a peptide to make strong inter-
actions in the HLA-DR P1 pocket is the crucial factor for
resistance to DM editing [23]. For HLA-DQ (and I-A)
proteins, there is not as much information on binding
specificity and DM susceptibility, but the P1 pocket is
smaller and less consequential energetically [24], and so
factors in addition to P1 interactions might play a greater
role for these proteins.
A different line of evidence implicates MHC confor-
mational change as a key feature determining DM
susceptibility. Painter et al. found that substitution of
DRa F54 resulted in MHC-peptide complexes highly
sensitive to DM editing and able to form relatively
stable DM complexes even with a large anchor residue
in the P1 pocket [7]. Structural analysis of the mutant
protein revealed conformational changes in the alpha
subunit 3–10 helix and extended strand region, smaller
but in the same regions as the MHCII conformational
changes observed in the DM-MHCII crystal structures.
Hou et al. investigated HLA-DQ2, an allele that is
relatively resistant to DM editing, and found that inser-
tion of a glycine residue at position DQa 53 in the
extended strand recovered DM susceptibility [25].
HLA-DQ2 has a deletion at this position relative to
most other MHCII proteins, but the deletion does not
dramatically change the MHC conformation in this
region [26]. How insertion of glycine at DQa 53
increases DM susceptibility is not known, but increas-
ing conformational flexibility would appear to be a likely
explanation. Using a gel mobility assay and a series of
DR1-binding peptides, Ferrante et al. observed two
different MHC-peptide conformers populated accord-
ing to peptide binding affinity, only one of which was a
substrate for DM editing [27]. All the peptides shared a
tyrosine at the P1 position, but differed at other, non-
anchor positions. These considerations lead to a model
whereby the ability of a MHC-peptide complex to adopt
a new conformation is the key feature determining DM
susceptibility.Current Opinion in Immunology 2014, 26:115–122 Most naturally occurring MHC-peptide complexes will
occupy the P1 pocket, and indeed usually the entire P-2
to P10 region. Whether the relative DM susceptibility of
these complexes is related to how frequently they vacate
the P1 pocket, or to how efficiently they populate a DM
conformer susceptible to editing, and whether these
properties are related in any straightforward way to pep-
tide sequence, remain topics for further investigation. To
date conformational properties have been investigated
only for a very few HLA-DR complexes, and DM
susceptibilities investigated for a somewhat larger set
of peptides but almost exclusively for a very few HLA-
DR alleles (primarily DRB1*0101). Thus at present there
are not enough empirical data available to resolve these
important questions about the sequence and structural
determinants for DM susceptibility.
Outstanding questions about the mechanism
of DM action
Several important questions remain about the molecular
mechanism of DM action. Despite the overall congruence
of DM-DR and DM-DO structures, the actual confor-
mation of the crucial region MHC-II a35–57 region is
quite different in two structures, with either aF51 or
aF54 occupying the P1 pocket (Figure 2a). These phenyl-
alanine residues are conserved, but not invariant, among
MHC-II sequences, and understanding their relative roles
might bear on the relative DM susceptibilities of MHC
alleles with differences at these positions. The relationship
of these trapped complexes to an actual reaction inter-
mediate is not clear, and the very basic mechanistic ques-
tion of whether the DM-bound MHC-II intermediate
contains one (destabilized) peptide [2,6], two (partially
bound) peptides [28,29], or no peptide at all [3,7],
remains to be established. Besides its mechanistic import-
ance, this issue relates to question of peptide competition
for MHC-II binding, important both for understanding the
factors that regulate the spectrum of peptides displayed
normally by antigen presenting cells and also for guiding
efforts to alter this spectrum therapeutically. Finally, none
of the mechanistic studies to date have addressed the
relationship between DM action and those of small mol-
ecule [30–32] and short peptide [33,34] modulators of
MHC-II peptide dissociation, which have been described
as having a DM-like mechanism of action. A possible
mechanism that could reconcile all these ways to promote
MHC-peptide dissociation would include an aspect of
facilitated dissociation by subsite occupancy [35], as
recently proposed for IgE-Fce receptor inhibitors [36].
In this mechanism, dissociation of a ligand with multiple
attachment points is facilitated by blocking only one of the
sites of interaction. It is possible that small molecules that
occupy a side-chain binding pocket [30–32], short peptides
that occupy only part of the peptide-binding site [33,34],
and DM-induced conformational changes that block
P1 pocket and/or hydrogen-bonding interactionswww.sciencedirect.com
HLA-DM and HLA-DO Mellins and Stern 119[2,3,6,7], all induce peptide dissociation by this mech-
anism.
Progress in elucidating the elusive role of DO
in immunity
In an important paper, Gu et al. report immunodefi-
ciency and autoimmunity in H2-O knockout mice
[37]. Previous biochemical and cellular work on H2-
O had identified potential roles for DO in regulating
antigen presentation [38–42] and in shaping the spec-
trum of MHC-II-bound peptides [41,42], but only very
limited immune changes were identified in knockout
mice [38,39]. Gu et al. show that H2-O/ mice spon-
taneously develop high titers of anti-nuclear antibodies.
Despite the production of autoantibodies, T-dependent
IgG antibody responses to model antigens are delayed,
perhaps due to the reduced frequency of marginal zone
B cells in these mice. Thus DO decreases immunity to
self-antigens while increasing immunity to (at least
some) foreign antigens. CD4+ T cells that developed
in H2-O/ mice were required for autoantibody pro-
duction and higher ANA titers were observed when B
cells also lacked H2-O. T cell receptor repertoire was
altered, as reflected by greater homeostatic proliferation
of H2-O/T cells when they were transferred into H2-
O/ (compared to H2-O+/+) hosts. The observations
from these mice argue that DO’s regulation of self-
peptide presentation is important in restraining periph-
eral activation of autoreactive CD4+ T cells, consistent
with Yi et al. [43]. In a separate avenue of research,
Kremer et al. showed that DO is required for efficient
MHC-II presentation of particular human self-antigens
[44]. Similarly, DO expression generally is required for
high levels of class II invariant chain peptide (CLIP)
presentation at the cell surface; new work from the
Pezeshki et al. shows that this increases binding of
particular superantigens, SEA and TSST-1 [45]. The
finding that HLA-DO is a competitive inhibitor of DM
action would appear to indicate that DO acts simply by
attenuating DM, and not, for example, by modulating
DM specificity [3], although Poluektov et al. have
proposed an additional role for HLA-DO in direct
interaction with MHC-II [46].
Gu et al. suggest that if DO is acting by inhibiting DM
that inhibition should be spatially or temporally
regulated to result in a qualitatively different spec-
trum of peptides presented on MHC-II [37], as has
been reported in class II peptide elution studies of B
cells with and without DO [40]. DO is relatively
unstable in the absence of DM and free DO does
not traffic beyond the ER [47], so most or all DO in an
antigen-presenting cell is associated with DM. How-
ever, there appear to be mechanisms that result in
differential steady state distribution of DM/DO com-
plexes and free DM within the endosomal pathway in
B cells, with DM/DO enriched in early endocyticwww.sciencedirect.com compartments and free DM enriched in late endoso-
mal/lysosomal compartments [48]. Within the latter,
evidence suggests that there is differential distribution
of DM and DM/DO [49]. Consistent with this prior
finding, Xiu et al. used B cell and HeLa cell transfec-
tants to show that DM redistributes to the limiting
membrane from the internal vesicles of lysosomal
multivesicular bodies though its interaction with
DO, in a process mediated by the sorting motif present
in the HLA-DO beta subunit cytoplasmic tail [50].
Jahnke et al. report evidence supporting ubiquitination
as a direct regulator of DO intracellular localization,
with additional indirect effects on endocytic machin-
ery [51]. Thus, intracellular sorting and localization
might provide the spatial regulation hypothesized by
Gu et al. to generate a different spectrum of self and
foreign peptide antigens bound to MHC-II in the
presence or absence of DO.
Role of DM in autoimmunity
Several papers have reported a requirement for DM
activity in development of type 1 diabetes (TID).
Hyperexpression of DO, with consequent reduced
DM function, inhibited T1D in NOD mice [43]. Direct
ablation of DM function in NOD mice, achieved by
gene targeting of NOD ES cells, also blocked diabetes
[52]. In the second model, reduced numbers of patho-
genic CD4 T cells were observed. The expression on
antigen-presenting cells of the NOD class II molecule I-
Ag7 is lower in both DO-overexpressing and DM-
deficient strains as compared to wild type NOD, reflect-
ing dependence of I-Ag7 on DM chaperoning. In these
models, the role of DM in autoimmunity is hypothes-
ized to be related to peripheral presentation of DM-
dependent disease-initiating peptide(s), with reduced
DM activity resulting in reduced presentation and
reduced disease pathology. In other studies of the role
of DM in the NOD model of type 1 diabetes, evidence
has been presented supporting a critical role in disease
pathology for CD4+ T cells that recognize DM-suscept-
ible complexes of I-A/insulin peptide, generated by
capture of extracellular peptide at the cell surface or
in re-cycling vesicles, locations where DM activity is
low. DM is hypothesized to edit out disease-related
peptide(s) during tolerance development, with reduced
DM activity resulting in increased tolerance to DM-
susceptible self-antigens [53]. Further, evidence has
been presented supporting a critical role in disease
pathology for insulin-reactive CD4+ T cells recognizing
a DM-independent/susceptible epitope [54]. An inte-
grated picture would suggest multiple roles for DM in
T1D pathogenesis. Notably, the DM-resistant DQ2
allele is a well-established high risk allele for human
TID, and a recent bioinformatic analysis based on
GWAS data indicates a DMB polymorphism with con-
sequences for risk for several autoimmune diseases,
including T1D [55].Current Opinion in Immunology 2014, 26:115–122
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The work described here provided long-sought answers
to questions in the class II antigen presentation field:
What is the conformation of a class II transition state
stabilized by DM? What is the mechanism of DO inhi-
bition of DM? And what are (at least some of) the
immunological consequences of DO deficiency? How-
ever, key issues remain. The molecular basis for the
difference in stability of transient DM/DR complexes
as compared to tight and essentially irreversible binding
of DM/DO complexes is not clear from current structural
and mutational analysis. The peptide sequence determi-
nants of DM susceptibility are not known, and the DM
susceptibility of HLA-DQ/peptide and HLA-DP/peptide
complexes has been investigated in few if any cases. The
contribution of DO in central tolerance has not been
directly addressed. The compartments and subdomains
where DM and DO localize in primary antigen presenting
cells are not known, nor is the function (if any) of DM
expressed at the cell surface. How do DO deficient mice
handle infection? These and other questions will shape
the next efforts in the field.
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